WO2004085383A1 - 2-シアノ-3-ヒドロキシ-n-(4-トリフルオロメチルフェニル)ヘプタ-2-エン-6-インアミドの製造法およびその結晶多形の製造法 - Google Patents
2-シアノ-3-ヒドロキシ-n-(4-トリフルオロメチルフェニル)ヘプタ-2-エン-6-インアミドの製造法およびその結晶多形の製造法 Download PDFInfo
- Publication number
- WO2004085383A1 WO2004085383A1 PCT/JP2004/003904 JP2004003904W WO2004085383A1 WO 2004085383 A1 WO2004085383 A1 WO 2004085383A1 JP 2004003904 W JP2004003904 W JP 2004003904W WO 2004085383 A1 WO2004085383 A1 WO 2004085383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- crystal
- solvent
- stirring
- crystals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
Definitions
- the present invention provides a compound of formula (I):
- the present invention provides a novel method for producing compound (I) having immunosuppressive activity, and a selective method for crystal polymorph comprising compound A, form B and form C crystals of compound (I).
- a novel method for producing compound (I) having immunosuppressive activity and a selective method for crystal polymorph comprising compound A, form B and form C crystals of compound (I).
- a selective method for crystal polymorph comprising compound A, form B and form C crystals of compound (I).
- Compound (I) is useful in the treatment of rheumatoid arthritis and chronic inflammatory diseases, immune or non-immune, such as graft-versus-host disease, reactions in transplantation, uveitis, etc., and cancer.
- the method is described in JP-A-5-310672 (Patent Document 1).
- the uniformity of the physical properties of a drug is essential for producing safe and effective drugs.
- Different crystalline forms of the same compound may have different physical properties. If the crystal form cannot be controlled, ie, a single crystal form cannot be stably formed, the quality of the drug obtained will vary irregularly from batch to batch. Therefore, producing a substance with uniform physical properties, that is, controlling the crystal form, is a very important issue for quality control of drugs.
- the present invention has been made to solve the above problems and problems, and is further based on the finding that compound (I) has a polymorph. Therefore, the present invention provides a method for producing compound (I) suitable for production on an industrial scale and a method for selectively producing a crystalline polymorph of compound (I).
- a method for producing a compound (I) comprising obtaining a compound (I) represented by the formula: Further, according to the present invention, by controlling the recrystallization temperature when recrystallizing the compound (I), the A-form crystal, the B-form crystal and the C-form crystal of the compound (I) can be selected individually.
- a process for the selective production of Form A, Form B and Form C crystals of compound (I), comprising the steps of: BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 shows an IR spectrum of a form crystal of the compound (I).
- FIG. 2 is an IR spectrum of Form 8 crystal of compound (I).
- FIG. 3 is an IR spectrum of a square crystal of the compound (I).
- FIG. 4 shows the results of a DSC endothermic test of the A-form crystal of compound (I).
- Fig. 5 shows the results of the DSC endothermic test of the B-form crystal of compound (I).
- Fig. 6 shows the results of the compound (I).
- FIG. 7 is an X-ray diffraction diagram of an octagonal crystal of compound (I), which is a measurement result of a C-type crystal of the compound by DSC endothermic test.
- FIG. 8 is an X-ray diffraction diagram of Form 8 crystal of compound (I).
- FIG. 9 is an X-ray diffraction pattern of a ⁇ 3 type crystal of the compound (: I).
- the reaction of the first step is carried out by reacting compound (I 1) with compound (1 I I) or a reactive derivative at the carboxy group thereof.
- Examples of the reactive derivative at the carboxy group of the compound (III) include an acid halide, an acid azide, an acid anhydride, a mixed acid anhydride, an active amide, an active ester, and the like.
- reactive derivatives include: acid halides; acid azides; symmetric acid anhydrides; substituted phosphoric acids (eg, dialkyl phosphoric acid, phenyl phosphoric acid, diphenyl phosphoric acid, dibenzyl phosphoric acid, or halogens).
- substituted phosphoric acids eg, dialkyl phosphoric acid, phenyl phosphoric acid, diphenyl phosphoric acid, dibenzyl phosphoric acid, or halogens.
- Phosphoric acid dialkyl phosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid (for example, methanesulfonic acid), aliphatic carboxylic acid (for example, acetic acid, propionic acid, butyric acid, isobutyric acid, pipelaric acid, sulfuric acid)
- Asymmetric acid anhydrides with acids such as acetic acid, isopenic acid, 2-ethylbutyric acid or trichloroacetic acid) or aromatic carboxylic acids (eg, benzoic acid);
- Any of the above reactive derivatives can be obtained by a conventional method.
- the reaction of the first step is usually performed in a solvent under cooling to heating.
- Solvents used in this reaction include esters such as ethyl acetate, ethers such as tetrahydrofuran, geethylether and dioxane, aprotic polar solvents such as acetone, acetonitrile, ⁇ , ⁇ -dimethylformamide and pyridine. , 1,2-dichloroethane, halogenated hydrocarbons such as chloroform and benzene, saturated or unsaturated hydrocarbons such as hexane, benzene and toluene, and mixtures of these solvents.
- compound (III) when compound (III) is used in the form of a free acid, for example, ⁇ , ⁇ , -dicyclohexylcarbodiimide, ⁇ -cyclohexyl- ⁇ , -morpholinoethyl Carbodiimide, ⁇ -cyclohexyl- ⁇ ,-(4-getylaminocyclohexyl) carbodiimide, ⁇ , ⁇ , -jetyl carbodiimide, ⁇ , ⁇ , -di To propyl carbodiimide, N-ethyl-N '-(3-dimethylaminopropyl) carbodiimide, ⁇ , ⁇ , -carbonylbis- (2-methylimidazole), pentamethylene ketene- ⁇ -cyclo Xylimine, diphenylketene- ⁇ -cyclohexylimin, ethoxyacetylene, 1-alkoxy-1-cycloethylene, trialky
- the reaction is preferably performed in the presence of the Vilsmeier reagent.
- this reaction can also be carried out in the presence of an acid such as an inorganic acid, an organic acid and a Lewis acid.
- Examples of the inorganic acid include sulfuric acid and hydrochloric acid
- examples of the organic acid include ⁇ -toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, and sulfosalicylic acid.
- boron trifluoride getyl ether complex, tin tetrachloride, titanium tetrachloride, yttrium triflate, scantium triflate and the like.
- Particularly preferred is di-toluenesulfonic acid.
- Reactions in the presence of acids usually involve, for example, benzene, toluene, xylene.
- the reaction is carried out in a non-polar solvent such as lorobenzene, which is immiscible with water, while heating and removing water generated as the reaction proceeds outside the reaction system, or in the presence of a dehydrating agent such as molecular sieve. Is preferably performed.
- this reaction involves the use of inorganic bases such as alkali metal bicarbonates, alkali metal carbonates and alkali metal hydroxides or tri (lower) alkylamines, pyridine, N- (lower) alkylmorpholines, N, N-di (lower)
- inorganic bases such as alkali metal bicarbonates, alkali metal carbonates and alkali metal hydroxides or tri (lower) alkylamines, pyridine, N- (lower) alkylmorpholines, N, N-di (lower)
- any organic base such as alkylaminopyridine, N, N-di (lower) alkylaniline and N, N-di (lower) alkylbenzylamine.
- the reaction in the second step is carried out by reacting the compound (IV) obtained above with a mixed acid anhydride of the compound (V) in a solvent.
- a mixed acid anhydride with (lower) alkyl carbonate or cycloalkyl cyclocarbonate is preferable.
- (lower) alkyl carbonate include methyl methyl carbonate, ethyl methyl carbonate, n-propyl carbonate, isopropyl carbonate, n-butyl carbonate, and s-butyl carbonate.
- Examples of carbonic acid-1-butyl and isoamyl carbonate include cycloalkyl carbonates such as cyclopentyl carbonate and cyclohexyl carbonate. In addition, those in which these chromates are replaced with bromide, fluoride, and iodide may be used.
- the mixed acid anhydride of the compound (V) is usually prepared in the presence of an inorganic base or an organic base in an organic solvent under cooling to heating.
- examples of the inorganic base, the organic base, and the organic solvent include those exemplified in the first step.
- the mixed acid anhydride of compound (V) thus obtained is isolated and purified by a conventional method. Can be used for the reaction with compound (IV) without isolation or purification
- the reaction in the second step is usually performed in a solvent under cooling to heating, as in the first step.
- the compound (I) thus obtained can be isolated and purified by a conventional method, but is preferably purified by recrystallization.
- Recrystallization solvents include alcohols such as methanol, ethanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol and t-butyl alcohol; ketones such as acetone and methyl ethyl ketone; methyl acetate; acetic acid Ethyl, esters such as isopropyl acetate, nitriles such as acetonitrile, ethers such as tetrahydrofuran and dioxane, and a mixed solvent of the above solvent miscible with water and water as a poor solvent, and a mixture of the above solvent and poor solvent Aliphatic hydrocarbons such as n-pentane, cyclopentane, n-hexane, cyclohexane, n-heptane or cycloheptane as solvents, aromatic hydrocarbons such as benzene, toluene, xylene or diisoprovire And a mixed solvent
- the recrystallizing compound (I) when recrystallizing compound (I), controlling the recrystallization temperature and / or the crystallization time allows the A-form crystal of compound (I) Form B crystals and Form C crystals can be selectively obtained. That is, the crystals of compound (I) are dissolved in a solvent, and this solution is kept under stirring at about 55 ° C .; up to 95 ° C., and if necessary, a poor solvent is added. By filtration, the IR (KBr) spectrum of FIG. 1, the DSC endothermic curve of FIG. 4, and the X-ray diffraction pattern of FIG. 7 are shown. Form A crystal of compound (I) having a characteristic peak at about 21.5 ° can be obtained.
- the compound (I) crystals are dissolved in a solvent, and the solution is kept under stirring at about 20 ° C to about 45 ° C, preferably at about 30 ° C to about 40 ° C. After the poor solvent was added, the precipitated crystals were collected by filtration to give the IR (KBr) spectrum in Fig. 2, the DSC endothermic curve in Fig. 5, and the X-ray diffraction pattern in Fig. 8.
- Form B of compound (I) can be obtained, which has characteristic peaks at about 6.2, about 12.5, and about 20.8 ° in FIG.
- Fig. 3 shows the IR (KBr) spectrum in Fig. 3, the DSC endothermic curve in Fig. 6, and the X-ray diffraction pattern in Fig. 9.The X-ray diffraction at 20 was approximately 6.2, 12.4, and 20.2 °. It is possible to obtain a C-type crystal of compound (I) characterized by having a peak. In the above method, the poor solvent is added when crystals are difficult to precipitate or crystallization must be promoted. If there is.
- the solvents mentioned as the recrystallization solvent for the compound (I) can be used, but from the viewpoint of yield and the like.
- Particularly preferred are alcohols such as methanol and isopropyl alcohol or acetone as a solvent and a combination of these solvents with water as a poor solvent or a combination of ethyl acetate as a solvent and n-heptane as a poor solvent.
- Form A above is produced by crystallization in a temperature range of about 55 to about 95 ° C.
- Form A crystals from crude crystals of Compound (I), for example,
- methanol is used as the crystallization solvent
- 0.8 to 80 times the amount of methanol (w / w) to the compound (I) and 0.5 to 50 times the amount of water as the poor solvent to methanol are used.
- Amount (v / v) can be used.
- the Form B crystal can be produced by crystallization in a temperature range of about 20 to about 45 ° C; preferably about 30 to about 40 ° C.
- a B-type crystal from the crude crystal of the compound (I) for example, when methanol is used as a recrystallization solvent, 40 to 160 times the amount of the compound (I) ( (w / w) methanol and water as a poor solvent can be used in an amount of 0.2 to 10 times (v / v) methanol.
- ethyl acetate When ethyl acetate is used as the recrystallization solvent, 4.5 to 18 times (w / w) of ethyl acetate to the compound (I) and n-heptane as the poor solvent are added to the ethyl acetate for 3 to 3 times. Up to 20 times (v / v) can be used.
- the above-mentioned C ⁇ crystals can be produced by performing crystallization in a temperature range of about 0 to about 15 ° C.
- the amount is 80 to 400 times the amount of the compound (I) ( (w / w) methanol and 0.1 to 5 times the volume of methanol as a poor solvent (v / v) can be used.
- ethyl acetate When ethyl acetate is used as the recrystallization solvent, 10 to 45 times (w / w) of ethyl acetate with respect to the compound (I) and n-heptane as the poor solvent are added to the ethyl acetate at a concentration of 0.1 to 45 times. 1 to 5 times (v / v) can be used.
- the compound (I) obtained by suspending the A-form, B-form or C-form crystals of the compound (I) as described above in a solvent and stirring the mixture under heating is controlled by heating the compound (I).
- the A-form, B-form and C-form crystals of I) can be selectively converted to other crystal forms, respectively.
- Form 8 crystal or Form C crystal of compound (I) or a mixture thereof is suspended in a solvent, and this suspension is maintained at about 55 ° C to 95 ° C with stirring, and then suspended. By filtering the crystals from the liquid, Form A crystals of compound (I) can also be obtained. Also, form A of compound (I) is suspended in a solvent, the suspension is kept at about 20 ° C to 45 ° C with stirring, and the crystals are collected by filtration from the suspension. Also, a B-type crystal of the compound (I) can be obtained.
- the solvents listed as the solvent for recrystallizing the compound (I) can be used.
- methanol or isopropyl is used as a solvent in terms of yield and the like.
- Particularly preferred are alcohols such as alcohols or acetones, and combinations of these solvents with water as a poor solvent, or combinations of ethyl acetate as a solvent and n-heptane as a poor solvent.
- the stirring time at a predetermined temperature required for the interconversion between the crystalline polymorphs is not particularly limited, but usually about 5 hours to about 72 hours is sufficient.
- methanol or ethyl acetate can be used. That is, when methanol is used as the solvent, methanol is used in an amount of 8 to 80 times (w / w) the amount of the B-form or C-form crystals of the compound (I) or a mixture thereof, and water as the poor solvent is used. 0.5 to 5 with respect to methanol
- ethyl acetate When using ethyl acetate, use 2.5 to 10 times (w / w) of ethyl acetate as the poor solvent with respect to the B-type crystal or C-type crystal of the compound (I) or a mixture thereof.
- -Heptane can be used 2 to 50 times (v / v) the amount of ethyl acetate.
- methanol or ethyl acetate can be used. That is, when methanol is used as the solvent, the amount of methanol is 40 to 160 times (w / w) the amount of the A-form crystal of compound (I), and the amount of water as the poor solvent is 0.2 to 0.2 to methanol. 10 times (v / V) can be used.
- (lower) alkyl as used in this booklet means (Ci Cj alkyl.
- each crystal form of compound (I) was examined based on the measurement results of the DSC endothermic test.
- the stability of these polymorphs was stable in the order of B-type crystal> C-type crystal> A-type crystal. It turned out to be.
- the mixture was concentrated again under reduced pressure until the liquid volume reached 400 L.
- IR (ATR method) (cm ⁇ S S11 ⁇ 2217, 1627, 1626, 1589, 1554, 1415, 1321, 1263, 1243, 1160, 1113, 1072, 841, 658.
- Example 2 The compound (IV) obtained in Example 1 was stirred under a nitrogen atmosphere at 25 to 30 ° C. 8
- Example 5 was completely identical to those of the compound (I) obtained in Example 2.
- This Form A crystal showed an endothermic reaction at 175 ° C in a DSC endothermic test, and exhibited characteristic beaks at 6.7, 13.4, and 21.5 ° in X-ray diffraction 20.
- the IR (KBr) spectrum, DSC endothermic curve and X-ray diffraction pattern of this crystal are shown in Fig. 1, Fig. 4 and Fig. 7, respectively.
- 5 g of crude crystals of the compound (I) obtained in Example 2 were dissolved in 5 OmL of acetone.
- This Form B crystal shows an endothermic reaction at 92 and 175 ° C in the DSC endothermic test, and has a characteristic peak at 6.2, 12.5, and 20.8 ° in X-ray diffraction 20.
- IR KBr (cm "1); 3311, 2217, 1635, 1614, 1594, 14 18, 1399, 1322, 1269, 1163 3 1125, 1116, 107 3 3 1020, 970, 843, 666 3 659, 592, 525.
- IR (ATR method) (cm-l; 33 1 1, 2 217, 1 627, 16 26, 15 89, 15 54, 141 5, 1 32 1, 1 263, 1243, 1 1 60, 1 1 1 3, 1072, 841, 6 58.
- This C-type crystal showed an endothermic reaction at 88 and 174.5 ° C in the DSC endothermic test, and showed characteristic peaks at 6.2, 12.4 and 20.2 ° in X-ray diffraction 26>.
- the IR (KBr) spectrum, X-ray diffraction pattern and DSC endothermic curve of this crystal are shown in Fig. 3, Fig. 6 and Fig. 9, respectively.
- IR KBr (cm " 1 ); 3309, 2221, 1590, 1554, 1417, 1388, 1328, 1162, 1118, 1072, 1018, 847, 664,
- the present invention relates to a process for producing compound (I), wherein carbonic acid carbonates used as an activating reagent are decomposed into alcohols and carbon dioxide after the reaction, so that almost so-called industrial waste is generated. It has the feature that it does not. Furthermore, since the method for producing compound (I) according to the present invention does not require severe reaction conditions, general-purpose equipment can be used, and the method for producing compound (I) can be used on an industrial scale as compared with the conventional method for producing compound (I). More suitable for the production of compound (I).
- the octamorphous crystal, the B-form crystal and the C-form of the compound (I) can be controlled by controlling the recrystallization temperature and / or the crystallization time. Crystals can be selectively and efficiently produced.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005504050A JPWO2004085383A1 (ja) | 2003-03-24 | 2004-03-23 | 2−シアノ−3−ヒドロキシ−n−(4−トリフルオロメチルフェニル)ヘプタ−2−エン−6−インアミドの製造法およびその結晶多形の製造法 |
EP04722662A EP1609778A1 (en) | 2003-03-24 | 2004-03-23 | Process for production of 2-cyano-3-hydroxy-n-(4-tri- fluoromethylphenyl)hept-2-en-6-ynamide and process for production of polymorphs thereof |
US10/550,099 US20060217440A1 (en) | 2003-03-24 | 2004-03-23 | Porcess for production of 2-cyano-3-hydroxy-n-(4-trifluoromethylphenyl)hept-2-en-6-ynamide and process for production of polymorphs thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-081335 | 2003-03-24 | ||
JP2003081335 | 2003-03-24 | ||
JP2003-176706 | 2003-06-20 | ||
JP2003176706 | 2003-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004085383A1 true WO2004085383A1 (ja) | 2004-10-07 |
Family
ID=33100355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003904 WO2004085383A1 (ja) | 2003-03-24 | 2004-03-23 | 2-シアノ-3-ヒドロキシ-n-(4-トリフルオロメチルフェニル)ヘプタ-2-エン-6-インアミドの製造法およびその結晶多形の製造法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060217440A1 (ja) |
EP (1) | EP1609778A1 (ja) |
JP (1) | JPWO2004085383A1 (ja) |
WO (1) | WO2004085383A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115838340A (zh) * | 2022-12-31 | 2023-03-24 | 辰欣药业股份有限公司 | 一种特立氟胺的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310672A (ja) * | 1992-01-08 | 1993-11-22 | Roussel Uclaf | 新規な2−シアノ−3−ヒドロキシエナミド、それらの製造法、それらを含有する製薬組成物及びそれらの薬剤としての使用 |
JPH10101636A (ja) * | 1996-09-12 | 1998-04-21 | Hoechst Ag | 2−シアノ−3,5−ジヒドロキシヘキサ−2−エンカルボキサミド誘導体 |
-
2004
- 2004-03-23 US US10/550,099 patent/US20060217440A1/en not_active Abandoned
- 2004-03-23 EP EP04722662A patent/EP1609778A1/en not_active Withdrawn
- 2004-03-23 JP JP2005504050A patent/JPWO2004085383A1/ja active Pending
- 2004-03-23 WO PCT/JP2004/003904 patent/WO2004085383A1/ja not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310672A (ja) * | 1992-01-08 | 1993-11-22 | Roussel Uclaf | 新規な2−シアノ−3−ヒドロキシエナミド、それらの製造法、それらを含有する製薬組成物及びそれらの薬剤としての使用 |
JPH10101636A (ja) * | 1996-09-12 | 1998-04-21 | Hoechst Ag | 2−シアノ−3,5−ジヒドロキシヘキサ−2−エンカルボキサミド誘導体 |
Also Published As
Publication number | Publication date |
---|---|
US20060217440A1 (en) | 2006-09-28 |
JPWO2004085383A1 (ja) | 2006-06-29 |
EP1609778A1 (en) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108601355B (zh) | 制备激酶抑制剂及其中间体的方法 | |
JP6699979B2 (ja) | シロドシンおよびその中間体の合成方法ならびに結晶フォーム | |
JP2014516072A (ja) | アピキサバン製造方法 | |
JP2010539101A (ja) | インテグラーゼ阻害剤の調製のためのプロセスおよび中間体 | |
JP7236433B2 (ja) | Lfa-1拮抗薬リフィテグラストを調製および精製するためのプロセス | |
JP2019523273A (ja) | ベリノスタットの多形形態、およびその調製のためのプロセス | |
KR100787293B1 (ko) | 중간물인 6.알파.,9.알파.-디플루오로-11.베타.,17.알파.-디히드록시-16.알파.-메틸-안드로스트-1,4-디엔-3-온 17.베타.-카르복실산을 제조하기 위한 산화 방법 | |
WO2006055964A2 (en) | Zolmitriptan crystal forms | |
CN110637009A (zh) | 用于制备4-甲氧基吡咯衍生物的中间体的方法 | |
ES2791187T3 (es) | Síntesis de dabigatrán | |
JP4330836B2 (ja) | ピペラジン誘導体の製造方法 | |
WO2008090046A1 (en) | Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone | |
JP5485138B2 (ja) | エチニルチミジン化合物の精製方法 | |
JP2004508378A (ja) | セファロスポリンの製造における中間体 | |
WO2004085383A1 (ja) | 2-シアノ-3-ヒドロキシ-n-(4-トリフルオロメチルフェニル)ヘプタ-2-エン-6-インアミドの製造法およびその結晶多形の製造法 | |
JP2000044541A (ja) | 1,3−ジアルキルピラゾール−4−カルボン酸エステルの製造法 | |
JP4294121B2 (ja) | ピリドンカルボン酸誘導体の製造方法およびその中間体 | |
JP2002167385A (ja) | 2−フェニルイミダゾ[1,2−a]ピリジン−3−アセトアミド類の製造方法 | |
JP2009114166A (ja) | ジベンゾオキセピン化合物の製造方法 | |
EP2155698A1 (en) | Novel thermodynamically stable polymorphic form-l of letrozole | |
EP0297019A1 (en) | Famotidine polymorphic form and preparation thereof | |
CN112272665B (zh) | 制备立他司特的方法 | |
JP3193597B2 (ja) | グリシン誘導体の製造方法 | |
JPH083162A (ja) | イミダゾピリジン誘導体及びその製法 | |
JP3061599B2 (ja) | ケトン類の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504050 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006217440 Country of ref document: US Ref document number: 10550099 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004722662 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004722662 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10550099 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004722662 Country of ref document: EP |